Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 14/20 | 0.45 |
| ▸ | CDK2 | P24941 | 13/20 | 0.45 |
| ▸ | KDR | P35968 | 12/20 | 0.45 |
| ▸ | JAK2 | O60674 | 5/20 | 0.45 |
| ▸ | TYK2 | P29597 | 3/20 | 0.45 |
| ▸ | JAK3 | P52333 | 3/20 | 0.45 |
| ▸ | CDC7 | O00311 | 2/20 | 0.45 |
| ▸ | PLK4 | O00444 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
| ▸ | PAK4 | O96013 | 2/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063299 | 0.91 | CDK1 (0.52) | CDK1CDK2KDRCDK7CDK9 | |
| SCHEMBL4064315 | 0.91 | CDK1 (0.49) | CDK1CDK2KDRJAK2TYK2 | |
| SCHEMBL4059734 | 0.90 | KDR (0.56) | CDK1CDK2KDRJAK2TYK2 | |
| SCHEMBL4059397 | 0.89 | CDK1 (0.45) | CDK1CDK2KDRJAK2TYK2 | |
| SCHEMBL13648760 | 0.88 | CDK1 (0.45) | CDK1CDK2KDRJAK2TYK2 | |
| SCHEMBL4060061 | 0.88 | CDK1 (0.43) | CDK1CDK2KDRJAK2TYK2 | |
| SCHEMBL4062377 | 0.87 | TBK1 (0.45) | CDK1CDK2KDRJAK2TYK2 | |
| SCHEMBL4060268 | 0.87 | CDK1 (0.49) | CDK1CDK2KDRJAK2TYK2 | |
| SCHEMBL13648759 | 0.87 | TBK1 (0.44) | CDK1CDK2KDRJAK2TYK2 | |
| SCHEMBL13648765 | 0.86 | CDK1 (0.46) | CDK1CDK2KDRJAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392662-B1 | CDK INHIBITING PYRIMIDINES, PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BAYER SCHERING PHARMA AG (DE) | 2009-01-07 | — | — | EP | claimed |
| US-7598260-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-06 | — | — | US | disclosed |
| US-7598260-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-06 | — | — | US | disclosed |
| EP-1392662-B1 | CDK INHIBITING PYRIMIDINES, PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BAYER SCHERING PHARMA AG (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | BRUMBY THOMAS | 2008-02-14 | — | — | US | disclosed |
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | BRUMBY THOMAS | 2008-02-14 | — | — | US | disclosed |
| US-7291624-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7291624-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7235561-B2 | Compound and a composition including such a compound | SCHERING AG (DE) | 2007-06-26 | — | — | US | disclosed |
| US-7235561-B2 | Compound and a composition including such a compound | SCHERING AG (DE) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK1, CDK6 | CDK1 2/4885CDK2 1/4885KDR 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.